Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.46 |
| ▸ | NRP1 | O14786 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.41 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30552516 | 0.96 | ACE (0.49) | ACENRP1OPRK1OPRM1NTSR2 | |
| SCHEMBL30422984 | 0.95 | ACE (0.47) | ACENRP1OPRK1OPRM1NTSR2 | |
| SCHEMBL34466206 | 0.94 | BDKRB2 (0.44) | ACENRP1OPRK1OPRM1NTSR2 | |
| SCHEMBL5507620 | 0.93 | NRP1 (0.48) | ACENRP1OPRK1OPRM1NTSR2 | |
| SCHEMBL5507610 | 0.93 | NRP1 (0.48) | ACENRP1OPRK1OPRM1NTSR2 | |
| SCHEMBL29802045 | 0.91 | OPRK1 (0.49) | ACENRP1OPRK1OPRM1NTSR2 | |
| SCHEMBL29721451 | 0.91 | ACE (0.45) | ACENRP1OPRK1OPRM1NTSR2 | |
| SCHEMBL30909415 | 0.91 | ACE (0.44) | ACENRP1OPRK1OPRM1MC4R | |
| SCHEMBL29906654 | 0.90 | NRP1 (0.50) | NRP1OPRK1OPRM1NTSR2NTSR1 | |
| SCHEMBL29721101 | 0.90 | ACE (0.45) | ACENRP1OPRK1OPRM1NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558420-B2 | Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin | SANOFI (FR) | 2026-02-24 | — | — | US | disclosed |
| US-20230399388-A1 | METHODS FOR TREATING INFLAMMATION USING ANTIBODIES TO KALLIDIN AND DES-ARG10-KALLIDIN | SANOFI (FR) | 2023-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558420-B2 | Methods for treating inflammation using antibodies to kallidin and des-Arg10-kallidin | BDKRB2, KLKB1, BDKRB1 | ACE 1466/4885NRP1 2257/4885OPRK1 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.